Enveric Biosciences Announces Patent Granted for Drug Candidate

Rubriques :

US patent includes broad claims for treating brain neurological disorders CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of protection for potential clinical indications for its EB-002 drug candidate through the issuance […]

Proclinical Staffing: HR Operations

pharmiweb.com - 10/Sep 09:59

Negotiable: Proclinical Staffing: Proclinical are working with a Biotechnology Company to recruit for an experience individual for the role of HR...

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

zacks.com - 04/Sep 15:14

RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

zacks.com - 04/Sep 15:14

RXRX plummets on mixed results from the mid-stage study of its lead candidate, REC-994, for treating a rare neurovascular condition.

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Study finds Alzheimer’s-like brain changes in long COVID patients

knowridge.com - 03/Sep 10:20

New research from the University of Kentucky’s Sanders-Brown Center on Aging has revealed that the cognitive impairments seen in long COVID patients...

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

drugs.com - 03/Sep 20:09

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....

Rubriques :

Enveric Biosciences Announces Patent Granted for Drug Candidate

Articles similaires

Proclinical Staffing: HR Operations

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

Recursion Stock Down Despite Meeting Goal in Brain Disease Study

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Study finds Alzheimer’s-like brain changes in long COVID patients

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

TAAR1 gene: A new key to mental health

KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE

Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg

Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg

Les derniers communiqués